Puxkandl, Viktoria
Currie, Antonia
Hoetzenecker, Wolfram
Altrichter, Sabine https://orcid.org/0000-0001-9955-385X
Article History
Received: 23 August 2022
Accepted: 3 July 2023
First Online: 26 July 2023
Declarations
:
: The patient gave full informed consent on the use of his medical history and all utilized pictures for this case report.
: All authors consent the publication of the manuscript.
: The authors have no conflicts of interest to declare that are relevant to the content of this article. Outside this topic: Sabine Altrichter has conducted studies for/was advisor for/was speaker for AstraZeneca, Allakos, ALK, CSLBehring, LeoPharma, Moxie, Novartis, Sanofi, Takeda, Thermofisher. Wolfram Hoetzenecker has conducted studies for/was advisor for/was speaker for Novartis, Eli Lilly, Bencard, ALK, Leo Pharma, Kyowa Kirin, Takeda, Sanofi-Aventis and AbbVie. The other authors state no conflict of interests.